Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking Paper Highlighting Data from Two Phase 3...
-
Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication Highlights the Critical Role of Inflammation...
-
Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks Topline Results with First-in-Class Non-Invasive Retinal Candidate APX3330 Expected in...
-
Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial...
-
Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in First Quarter NDA Filing on Track for Late...
-
FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials ...
-
FARMINGTON HILLS, Mich., April 26, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
FARMINGTON HILLS, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...